Jaka jest cena za Psyence Biomedical Ltd. (PBM)

Cena za Psyence Biomedical Ltd. (PBM) wynosi $3.20

Jaka jest kapitalizacja rynkowa dla Psyence Biomedical Ltd. (PBM)

Kapitalizacja rynkowa dla Psyence Biomedical Ltd. (PBM) wynosi $60.86K

Zyski Psyence Biomedical Ltd. (PBM)

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Rok	Zyski	Zmień
Za mało danych dla podanych dat.

Rok

Zyski

Zmień

Za mało danych dla podanych dat.

Firma	Zyski	Różnica w zyskach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Firma

Zyski

Różnica w zyskach

Kraj